149805-92-5

Basic information

• Product Name: 6-(DIMETHYLAMINO)NICOTINALDEHYDE
• Synonyms: 6-(DIMETHYLAMINO)NICOTINALDEHYDE;3-Pyridinecarboxaldehyde, 6-(dimethylamino)- (9CI);6-(dimethylamino)nicotinaldehyde(SALTDATA: FREE);3-Pyridinecarboxaldehyde, 6-(dimethylamino)-;6-(diMethylaMino)-3-Pyridinecarboxaldehyde;6-(Dimethylamino)pyridine-3-carboxaldehyde, 2-(Dimethylamino)-5-formylpyridine;6-(N,N-DiMethylaMino)nicotinaldehyde;6-(diMethylaMino)pyridine-3-carbaldehyde
• CAS NO: 149805-92-5
• Molecular Formula: C₈H₁₀N₂O
• Molecular Weight: 150.18
• Product Categories: ALDEHYDE;PYRIDINE;Building Blocks
• Mol File: 149805-92-5.mol
• Article Data: 8

Chemical Properties

• Melting Point: 57-59°
• Boiling Point: 286.2°C at 760 mmHg
• Flash Point: 126.9°C
• Appearance: /
• Density: 1.135g/cm³
• Vapor Pressure: 0.00267mmHg at 25°C
• Refractive Index: 1.602
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 5.44±0.10(Predicted)
• CAS DataBase Reference: 6-(DIMETHYLAMINO)NICOTINALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(DIMETHYLAMINO)NICOTINALDEHYDE(149805-92-5)
• EPA Substance Registry System: 6-(DIMETHYLAMINO)NICOTINALDEHYDE(149805-92-5)

Safety Data

• Hazard Codes: Xn
• Statements: 22-43
• Safety Statements: 36/37
• HazardClass: IRRITANT
• Hazardous Substances Data: 149805-92-5(Hazardous Substances Data)

Usage

General Description

6-(dimethylamino)nicotinaldehyde is a chemical compound with the molecular formula C9H11NO. It is a derivative of nicotinic acid and is often used in organic synthesis and as a reagent in chemical reactions. 6-(DIMETHYLAMINO)NICOTINALDEHYDE is known for its ability to act as a Schiff base, a type of molecule that forms when a primary amine reacts with a carbonyl compound. 6-(dimethylamino)nicotinaldehyde is commonly used in the production of pharmaceuticals and other organic compounds due to its versatile chemical properties and its ability to participate in a wide range of chemical reactions.

InChI:InChI=1/C8H10N2O/c1-10(2)8-4-3-7(6-11)5-9-8/h3-6H,1-2H3

Upstream product

• 23100-12-1 6-chloronicotinylaldehyde 
• 124-40-3 dimethyl amine 
• 68-12-2 N,N-dimethyl-formamide 
• 154924-17-1 N'-(5-cyanopyridin-2-yl)-N,N-dimethylformamidine 
• 26163-07-5 5-bromo-2-dimethylaminopyridine 
• 20485-44-3 2,3-dimethyl-2,3-diaminobutane 
• 5683-33-0 2-(Dimethylamino)pyridine 

Downstream Products

• 1428973-28-7 5-(((3-methoxyphenyl)imino)methyl)-N,N-dimethylpyridin-2-amine 
• 1428970-00-6 2-(6-(dimethylamino)pyridin-3-yl)-1-(1H-indol-3-yl)-2-((3-methoxyphenyl)amino)ethanone 
• 1620092-89-8 (E)-5-(2,6-dichlorostyryl)-2-(N,N-dimethylamino)pyridine 
• 1620092-87-6 (E)-5-(2-chloro-6-fluorostyryl)-2-(N,N-dimethylamino)pyridine 
• 1620092-84-3 (E)-5-(2,6-difluorostyryl)-2-(N,N-dimethylamino)pyridine 
• 1349698-33-4 tert-butyl (4-{(E)-2-[6-(dimethylamino)pyridin-3-yl]vinyl}phenyl)methylcarbamate 

Relevant articles and documents

COMPOUND, ADHESIVE COMPOSITION, POLARIZER AND DISPLAY APPARATUS

The present specification relates to a compound represented by chemical formula 1, an adhesive composition comprising the same, a polarizing plate, and an image display apparatus. By using the compound described in the present specification as the adhesive composition for the polarizing plate, it is possible to provide the adhesive composition having excellent UV blocking performance and exhibiting excellent durability.

Synthesis and luminescence properties of near-infrared N-heterocyclic luciferin analogues for in vivo optical imaging

As a means of achieving highly sensitive bioluminescence imaging of deep tissues utilizing the firefly luciferin-luciferase (L-L) reaction, we previously reported a luciferin analogue, AkaLumine, which exhibits high cell-permeability and emits near-infrar

N-SULFONYLATED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE

The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sj?gren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).